Skip to content
Equities Orbis

Equities Orbis

Stocks of the World, Revealed.

  • AI
  • Software
  • Utilities
  • Commodities
  • Space
  • Biotech
  • Industrials
  • Construction
  • Financials
  • Opinion
  • Macro
  • Crypto
  • Quantum

Author: Romeo Kuok

Romeo Kuok is a seasoned executive and investor with deep roots in the crypto and technology sectors. He is the Chairman of the Board for OT Inc. and also a partner at a leading Asian multi-family office. He held leadership roles at two global top-tier cryptocurrency exchanges. With over a decade of experience in go-to-market strategy and early-stage investing, Romeo's portfolio spans AI, robotics, and cryptocurrency. He has been an LP in top funds across North America and Asia, accessing unicorns such as SpaceX and TikTok. He is notably the largest personal angel investor in several high-return projects, including DeAgentAI and Sonic, which achieved returns of dozens of times post-TGE. His direct investments also include Puffer Finance and Solv Protocol.
The WFE Supercycle: Why Applied Materials is Leading the AI Infrastructure Breakout
AI

The WFE Supercycle: Why Applied Materials is Leading the AI Infrastructure Breakout

Romeo KuokJune 18, 2026June 18, 2026

Applied Materials surged 9% to lead the S&P 500 on Wednesday as Citi raised its price target to $710 and…

The $60 Billion Flex: How SpaceX’s Cursor Acquisition Changes the AI Arms Race
AI

The $60 Billion Flex: How SpaceX’s Cursor Acquisition Changes the AI Arms Race

Romeo KuokJune 17, 2026June 17, 2026

SpaceX’s $60 billion all-stock acquisition of Cursor parent Anysphere—announced just three trading days after its $75 billion IPO—demonstrates the new…

The $85 Billion Endorsement: Why Nvidia’s First Debt Sale Since 2021 Signals Unprecedented Strength
AI

The $85 Billion Endorsement: Why Nvidia’s First Debt Sale Since 2021 Signals Unprecedented Strength

Romeo KuokJune 16, 2026June 16, 2026

Nvidia’s first corporate bond sale since 2021 attracted $85 billion in investor demand—a 4.25x oversubscription that allowed the chipmaker to…

The AI Sovereign and Its Shadow: Valuing Arm Holdings and SoftBank Group
AI

The AI Sovereign and Its Shadow: Valuing Arm Holdings and SoftBank Group

Romeo KuokJune 15, 2026June 15, 2026

The semiconductor landscape has fractured into two distinct realms: the foundries that manufacture silicon and the architects that define its…

The Great Musk Migration: Why SpaceX’s IPO is Crushing Tesla Stock
Space

The Great Musk Migration: Why SpaceX’s IPO is Crushing Tesla Stock

Romeo KuokJune 15, 2026June 15, 2026

SpaceX’s record-shattering $2.2 trillion debut creates a structural capital rotation out of Tesla, as investors finally gain direct exposure to…

The Legitimate Challenger: Why AMD’s 6-Gigawatt Meta Deal Changes Everything
AI

The Legitimate Challenger: Why AMD’s 6-Gigawatt Meta Deal Changes Everything

Romeo KuokJune 13, 2026June 13, 2026

Citi’s double upgrade to Buy with a $575 price target validates AMD as a credible AI GPU challenger. The 6-gigawatt…

The $1.78T Reality Check: How to Trade the SpaceX IPO Debut
Space

The $1.78T Reality Check: How to Trade the SpaceX IPO Debut

Romeo KuokJune 12, 2026June 12, 2026

The largest IPO in Wall Street history debuts today at a $1.78 trillion valuation. Retail orders exceed $100 billion. But…

The $553B Backlog: Why Oracle is the Quiet Kingmaker of the AI Era
AI

The $553B Backlog: Why Oracle is the Quiet Kingmaker of the AI Era

Romeo KuokJune 10, 2026June 10, 2026

While global markets navigate the dual headwinds of escalating US-Iran military strikes and impending CPI inflation data, the most consequential…

Mapping the $1.8T Frontier: The Space Industry Supply Chain
Space

Mapping the $1.8T Frontier: The Space Industry Supply Chain

Romeo KuokJune 8, 2026June 8, 2026

The space industry is undergoing a paradigm shift, transitioning from a domain dominated by government agencies to a rapidly expanding…

The GLP-1 Arms Race: Eli Lilly, Novo Nordisk, and the Battle for a $150 Billion Market
Biotech

The GLP-1 Arms Race: Eli Lilly, Novo Nordisk, and the Battle for a $150 Billion Market

Romeo KuokJune 8, 2026June 8, 2026

The glucagon-like peptide-1 (GLP-1) receptor agonist market has evolved from a niche diabetes treatment category into the most lucrative pharmaceutical…

The Global AI Reckoning: Why Samsung’s 10% Crash is a Forced-Selling Gift
AI

The Global AI Reckoning: Why Samsung’s 10% Crash is a Forced-Selling Gift

Romeo KuokJune 8, 2026June 8, 2026

The semiconductor massacre that began on Wall Street last Friday has metastasized into a global contagion. On Monday, June 8,…

Posts pagination

1 2 Next
Equities Orbis
  • About Us
  • Contact
  • Submit Your Post
OT Media Inc.

The AI Oracle

Crypto Sybil

Equities Orbis

OT Public Relations

Copyright © 2026 Equities Orbis

  • English
  • 简体中文 (Chinese (Simplified))